Drugs / ADL5859
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00979953 | Oct 2009 → Apr 2010 | osteoarthritis, knee | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00603265 | Nov 2007 → Aug 2008 | neuropathy, painful, peripheral neuropathy | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00626275 | Oct 2007 → Sep 2008 | rheumatoid arthritis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00993863 | Jun → Sep 2007 | — | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADL5859 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00993863 ↗ |
| Action | Activate | “Delta opioid receptor agonist” CHEMBL494480 ↗ |
| Modality | Small molecule | — CHEMBL494480 ↗ |
| Route | Oral | “administered orally” NCT00603265 ↗ |
| Target | OPRD1 | “Delta opioid receptor agonist” CHEMBL494480 ↗ |